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Concise report
The predictive value of serum S100A9 and response
to etanercept is not confirmed in a large UK
rheumatoid arthritis cohort
Samantha Louise Smith1, Darren Plant2, Stephen Eyre1, Kimme Hyrich3,
Ann W. Morgan4, Anthony G. Wilson5, John D. Isaacs6 and Anne Barton1,2
Abstract
Objective. The aim was to correlate protein concentrations of S100A9 in pretreatment serum samples with
response to the tumour-necrosis factor (TNF) inhibitor drugs etanercept in a large UK replication cohort.
Methods. Pretreatment serum samples from patients with RA (n = 236) about to commence treatment with
etanercept had S100A9 serum concentration measured using an ELISA. Following the experimental pro-
cedure, S100A9 concentrations were analysed with respect to EULAR response.
Results. No evidence of association between S100A9 concentration and EULAR response to the TNF-
inhibitor biologic drug etanercept was observed following multinomial logistic regression analysis (non-
responder vs moderate responder, P = 0.957; and non-responder vs good responder, P = 0.316).
Furthermore, no significant associations were observed when correlating pretreatment S100A9 concen-
trations with clinical parameters of disease activity (P> 0.05).
Conclusion. In the largest replication cohort conducted to date, no evidence for association was
observed to support the use of S100A9 as a clinical biomarker predictive of response to the TNF-inhibitor
biologic drug etanercept.
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Rheumatology key messages
. This is the first study to attempt replication of the S100A9 protein biomarker in a large Caucasian RA cohort.
. The S100A9 protein biomarker is not predictive of EULAR response to etanercept in RA.
Introduction
Biologics have revolutionized the treatment of RA, greatly
benefitting the majority of patients receiving them. It is
known that early and effective treatment is key in order
to minimize joint damage [1, 2], but biologics are pre-
scribed on what is essentially a trial-and-error basis, and
effective treatment is not always achieved. In fact, up to
3040% of patients on biologics fail to respond satisfactor-
ily, and the disease can continue to progress, potentially
resulting in increased disability. To date, a reliable biomarker
predictive of response to biologics has yet to be identified
despite being the aim of precision medicine initiatives. The
necessity for such a biomarker was re-emphasized by a
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study which demonstrated that patients may continue their
current regime despite an inadequate response for far >6
months [3], which is the time point at which the National
Institute for Health and Care Excellence recommend switch-
ing to an alternative biologic [4].
The S100 protein family could provide one such promis-
ing biomarker. These multifunctional proteins have been
found to be upregulated in inflammatory disorders, includ-
ing RA [57], levels commonly correlate with clinical mar-
kers of disease activity (such as ESR and CRP) [813], and
they have been found to be suppressed (both locally at the
site of inflammation and distally within the circulatory
system) following treatment with biologics [8, 10, 1315]. In
fact, a recent study has investigated the predictive value of
S100A8, S100A9 and S100A8/A9 in pretreatment serum
samples collected from RA patients (n = 22), using both
mass spectrometry (relative quantification) and ELISAs (ab-
solute quantification). It was demonstrated that increased
levels of S100A9 before treatment (using both relative and
absolute quantification) were predictive of response to the
TNF-inhibitor biologic drug etanercept (P = 0.023) [16]; how-
ever, no significant differences were observed when corre-
lating absolute levels of S100A8 and S100A8/A9 with the
response phenotypes. It is important that replication of the
S100A9 association be attempted in independent cohorts in
order to confirm the correlation with treatment response.
The aim of this research was, therefore, to replicate the as-
sociation with S100A9 in a larger cohort of UK RA patients
about to commence treatment with etanercept.
Methods
Patient selection
Patients with RA were selected from the Biologics
Prospective Study, the prospective arm of the Biologics
in RA Genetics and Genomics Study Syndicate (BRAGGSS),
which recruits patients who are about to commence treat-
ment with biologic drugs from >50 sites across the UK,
described in detail previously [17]. Patients provide blood
samples and psychological and clinical information. This is
repeated after 3, 6 and 12 months. As such, disease activity
in 28-joints (DAS28) scores using four variables (the number
of tender and swollen joints, ESR/CRP and patient global
assessment score) can be calculated before and after treat-
ment [18]. The BRAGGSS study was approved by National
Research Ethics Service Committee North West—Greater
Manchester South (Research Ethics Committee Ref: 04/
Q1403/37). This approval included the present study, so
no additional approval was required for this study.
Inclusion criteria for this study were as follows.
Participants were: Caucasian;>18 years old; fulfilled the
1987 ACR criteria for RA; gave written informed consent;
were about to commence treatment with the biologic drug
etanercept; and had an available pretreatment serum
sample for analysis.
Defining treatment response
Clinical effectiveness was assessed using the EULAR
classification criteria [19]. A good response was defined
as a follow-up DAS28 joints of 43.2 and having
decreased from the pretreatment DAS28 score by>1.2.
A non-response was defined as having a DAS28 score
that decreased <0.6 from the pretreatment DAS28 score
or decreased between 0.6 and 1.2 but having an end
score of>5.1. Moderate response was classified when
responses fell intermediate to these two extremes.
Serum collection
Upon receipt, blood samples (previously collected into
plain blood tubes) were centrifuged at 1845 RCF for
10 min. After centrifugation, the serum was aliquotted
and stored at 80 C until required.
ELISA
Concentrations of S100A9 were determined in pre-
treatment serum samples using an ELISA according to
the manufacturer’s instructions (Cusabio, Hubei
Province, China). The detection range for the assay was
4.6900 ng/ml; if a concentration outside this range was
recorded, the sample was diluted and the assay repeated.
Likewise, if duplicate samples differed by>20%, the
assay was repeated. Absorbance was measured using
the SpectraMax Plus384 Absorbance Microplate Reader
(Molecular Devices, CA, USA), with 450 nm as the primary
wavelength and 540 nm for wavelength correction. All
samples and standards were assayed in duplicate.
Statistical analysis
All analyses were conducted in STATA/SE v11.2 [20].
KruskalWallis rank sum and analysis of variance tests
were used to assess the relationship between baseline
clinical/demographic data and EULAR response.
Multinomial logistic regression was conducted to deter-
mine the relationship between pretreatment S100A9 con-
centrations and EULAR response, using non-response as
the base outcome. Covariates, in terms of the baseline
characteristics (i.e. age at baseline) were added to the
model if statistically different between the response
phenotypes. Spearman rank correlations were conducted
to determine the relationship between pretreatment
S100A9 concentrations and clinical parameters (i.e. CRP
and pretreatment DAS28 scores). A value of P< 0.05 was
considered statistically significant for all analyses. Power cal-
culations were performed using G*Power version 3.1.2 [21].
Results
Two hundred and fifty-four pretreatment serum samples
were available for analysis. Owing to limited reagents, 18
samples were excluded because the duplicate samples
differed by >20% or the concentration was outside the
range of the standard curve; this left 236 samples for ana-
lysis. Using the EULAR classification criteria, this equated
to 44 non-responders, 98 moderate responders and 94
good responders. For the majority of the samples, the
response was assessed at 3 months (n = 200), whereas
for the remainder, the response was assessed at 6
months (n = 36) whenever response could not be
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calculated at 3 months. Cohort characteristics for these
236 samples are listed in Table 1.
Mean (S.D.) S100A9 concentrations for the three EULAR
response phenotypes were 183.8 (109.6) ng/ml in non-re-
sponders, 183.7 (109.5) ng/ml in moderate responders
and 165.5 (91.7) ng/ml in good responders. Using non-
response as the base outcome, multinomial logistic re-
gression was used to determine the association between
pretreatment S100A9 concentrations and EULAR re-
sponse, with concurrent DMARD use and baseline
DAS28 score as covariates. This resulted in non-signifi-
cant associations [non-responder vs moderate responder,
P = 0.957, odds ratio, OR (95% confidence interval (CI):
1.0 (0.997, 1.003); and non-responder vs good responder,
P = 0.316, OR (95% CI): 0.998 (0.995, 1.002); Fig. 1].
Multivariate logistic regression comparing moderate and
good responders gave a P-value of 0.225, OR (95% CI):
0.998 (0.995, 1.001). Additionally, using a multivariate lo-
gistic regression model, the analysis was repeated after
the grouping of moderate and good responders into a
single responder phenotype [P = 0.574, OR (95% CI):
0.999 (0.996, 1.002)].
As the previously reported association was observed in
patients receiving a combination of etanercept and MTX,
the analysis was repeated after the exclusion of patients
not receiving concurrent DMARDs (n = 42); however, this
did not significantly alter the findings [non-responder vs
moderate responder, P = 0.763, OR (95% CI): 1.00 (0.997,
1.004); and non-responder vs good responder, P = 0.206,
OR (95% CI): 0.998 (0.994, 1.001)].
Further analysis was conducted to investigate whether
there was a correlation between pretreatment S100A9
concentrations in serum and clinical baseline parameters,
as it has previously been demonstrated that pre-
treatment concentrations of the family of S100 proteins
(namely S100A8/A9) correlate with clinical markers of dis-
ease activity such as DAS28 scores (baseline and out-
come), CRP and ESR [8, 10, 1315]; however, no
significant correlations were observed within this data
set (P > 0.05).
DAS28 scores were also available at 6 months for 173
of these patients, in line with the previously reported study
outcome assessment time point [16]; however, after the
exclusion of moderate responders and those not on con-
current DMARD treatment, this equated to 90 patients
available for further analysis at 6 months (22 non-re-
sponders and 68 responders). Multivariate logistic regres-
sion between these two phenotypes yielded a non-
significant association [P = 0.353, OR (95% CI): 0.997
(0.993, 1.003)].
Discussion
It has previously been reported that pretreatment serum
concentrations of the protein S100A9 correlate signifi-
cantly with response to treatment with the TNF-inhibitor
biologic drug etanercept (P = 0.023) [16]. That was the first
report of a pretreatment protein biomarker successfully
correlating with response to etanercept and, therefore, it
is important to replicate the association. However, in con-
trast to the previous study, in the present large, well-pow-
ered replication cohort, we found no evidence to support
the use of pretreatment serum S100A9 concentrations as
a predictor of response to etanercept (non-responders vs
moderate responders, P = 0.957; and non-responders vs
good responders, P = 0.316).
Furthermore, we found no statistically significant asso-
ciation with DAS28 at follow-up (when relative quantifica-
tion using mass spectrometry was found to be correlated
with 6 month DAS28 scores within the original study, P
= 0.016 [16]) or with baseline DAS28, CRP, swollen joint
count or tender joint count, which is again in contrast to
previous studies investigating other members of the S100
family [8, 9, 13].
A strength of the present study was the large sample
size tested (n = 236) in comparison with the original cohort
(n = 22), reducing the chance of a false-negative result. For
example, using G*Power 3.1.2, in order to achieve 80%
power to detect moderate to large differences in protein
abundance between the response phenotypes at a
TABLE 1 Baseline characteristics of the 236 serum samples analysed for S100A9
Cohort characteristics
Non-responders
(n =44)
Moderate responders
(n =98)
Good responders
(n =94) P-value
Gender, female, n (%) 39 (88.6) 78 (79.6) 73 (77.7) 0.303a
Age at baseline, mean (S.D.), years 58.3 (11.9) 58.9 (11.5) 55.4 (11.7) 0.111b
Concurrent DMARDs, n (%) 42 (95.5) 70 (71.4) 82 (87.2) <0.001a
DAS28 score at baseline, median (IQR) 5.6 (5.06.3) 6.1 (5.56.6) 5.8 (5.16.2) 0.0032c
DAS28 score at outcome, mean (S.D.) 5.3 (4.95.7) 4.2 (3.64.6) 2.4 (1.82.8) <0.001b
Change in DAS28 score, mean (S.D.) 0.18 (0.66) 1.9 (0.86) 3.5 (1.00) <0.001b
TJC, median (IQR) 14 (1020) 16 (1122) 13.5 (919) 0.047c
SJC, median (IQR) 8 (311) 9 (612) 9 (613) 0.176c
CRP, median (IQR) 9.3 (3.521.7) 15 (7.331.2) 10 (3.527.2) 0.106c
HAQ, median (IQR), n 2 (1.32.4), 25 1.8 (1.32.1), 67 1.6 (1.32), 66 0.152c
aCalculated using 2 test. bCalculated using one-way analysis of variance. cCalculated using KruskalWallis test. DAS28:
disease activity scores in 28-joints ; IQR: interquartile range; SJC: swollen joint count; TJC: tender joint count.
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significance level (a) of 0.05 and using a one-tailed distri-
bution, 31 non-responders and 125 responders would
have been needed. However, there are several possible
reasons for the lack of replication. First, moderate re-
sponders were included within the present analysis as
compared with the original study where they were
excluded. However, following multinomial logistic regres-
sion, comparing non-responders with good responders,
no evidence for association was detected (P = 0.316). In
fact, moderate responders demonstrated the most similar
S100A9 signature to non-responders, suggesting that the
inclusion of moderate responders was not a confounding
issue. Second, a major difference between the two stu-
dies is that the response to etanercept was predominantly
assessed at 3 months in the present study as compared
with the 6 month time point in the original report.
However, further investigation following stratification by
the assessment time point did not materially alter the con-
clusions (data not shown).
Another reason for the lack of replication could be at-
tributable to the fact that the previously reported study
also used mass spectrometry to assess further the relative
abundances of S100A9 protein peptides within patient
serum samples. The authors reported that responder pa-
tients overexpress three protein peptides that are not
expressed in non-responders and, subsequently, ac-
counted for this within their analyses by normalizing
across the data set; this normalization step could there-
fore explain the discordant association. However, the
technology was not available for use in the present
study, and if, indeed, the S100A9 association is depend-
ent upon normalization for peptide abundances, it seems
unlikely that this biomarker would be readily adopted for
routine use in clinics. Furthermore, the original study de-
tected only a modest association of S100A9 as a bio-
marker for response to etanercept, with sensitivity and
specificities that are considered too low to be adopted
for widespread implementation (Receiver operating char-
acteristics sensitivity, 83%; specificity, 70%).
Another consideration that needs to be taken into ac-
count is the way in which serum samples are collected
and processed. As part of the BRAGGSS cohort, blood
samples for serum collection are shipped via postal ser-
vices, resulting in a median lag time of 15 days before the
blood sample is received and processed. This is an im-
portant factor to take into account because proteins may
be prone to degradation during this period at room tem-
perature and this may explain the lack of replication be-
tween the present study and the previously reported
association. As far as can be determined, S100 protein
FIG. 1 Pretreatment serum S100A9 concentrations grouped according to EULAR response phenotypes
Absolute quantification of S100A9 from baseline serum samples in non-responders, moderate responders and good
responders assessed by sandwich ELISA. The upper and lower quartiles are represented as the upper and lower bounds
of the box, whilst the line within the box represents the median. The whiskers represent the minimal and maximal values.
Outliers are represented as small dots.
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stability has been investigated in serum samples only for
S100A12. It was demonstrated that for freshly drawn
blood left at room temperature for up to 48 h before sep-
aration, the stability was highly dependent upon the tube
into which the blood was drawn. For example, blood
drawn into empty tubes, EDTA tubes or heparin tubes
demonstrated increased S100A12 concentrations over
time, whereas blood drawn into serum gel tubes demon-
strated stable concentrations [22]. Furthermore, up to 10
freezethaw cycles did not significantly impact upon
serum S100A12 concentrations at 20 C (P = 0.26) or
70 C (P = 0.30), and serum concentrations were stable
for 6 months at 20 C [22]. The delay between blood
draw and sample processing was considered as a poten-
tial confounder in the present study. However, following
multinomial logistic regression to compare S100A9 con-
centrations using a lag time of 1 day as the base compari-
son, no significant associations (P < 0.05) were observed
(data not shown). This suggests that S100A9 is stable at
room temperature for extended periods and was not
therefore the reason for the discordant association be-
tween the present study and the previously reported
observation.
Of note, the protein family of S100 proteins have con-
sistently been reported to decrease significantly following
treatment with biologics and, in some cases, this was sig-
nificant following a mere 4 weeks of treatment [8, 10,
1315]; however, S100A9 has not yet been tested to our
knowledge. It could be that S100A9 is an early pharma-
codynamic marker of response, but this will require further
investigation in follow-up serum samples.
Conclusion
In summary, the present study has conducted the largest
replication cohort to date for S100A9, but no evidence for
association with response to the TNF-inhibitor biologic
etanercept or with subcomponents to the DAS28 score
was observed.
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